CeriBell shows a strong technical breakout, robust growth, and a perfect earnings beat streak, but cash burn keeps quality below the engine's floor and heavy insider selling has tripped the insider gate, arguing for caution despite the momentum.
Thesis pillars
- Cash Burn Below Quality Floor↑Improving
- Breakout Momentum With Growth↑Improving
- Heavy Insider Selling Signal→Stable
- +1 more pillar — see the Why tab for full reasoning
CeriBell, Inc. (CBLL) Stock Analysis
Healthcare · Medical Devices
Sell if holding. Engine safety override at $22.91: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 6.0/10. Specifically: Below-average business quality.
CeriBell has developed the Ceribell System, an FDA-cleared point-of-care EEG platform paired with Clarity, an AI-powered algorithm for detecting seizures and, since a December 2025 clearance, delirium in critically ill patients. The company generated 88% gross margins in fiscal... Read more
Sell if holding. Engine safety override at $22.91: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 6.0/10. Specifically: Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 6.0/10, moderate confidence.
Passes 6/8 gates (positive momentum, no SEC red flags, news boost analyst 0.60, earnings proximity 82d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
Recent developments
updated 2026-08-13Recent Developments — CeriBell, Inc.
Latest news
- NEWS Canaccord Genuity Maintains Buy on CeriBell, Raises Price Target to $26 — benzinga Aug 11, 2026 positive
- NEWS BTIG Reiterates Buy on CeriBell, Maintains $28 Price Target — benzinga Aug 11, 2026 neutral
- NEWS CeriBell Raises FY2026 Sales Guidance from $112.000M-$116.000M to $114.000M-$117.000M vs $113.979M Est — benzinga Aug 10, 2026 positive
- NEWS CeriBell Q2 EPS $(0.51) Misses $(0.47) Estimate, Sales $28.097M Beat $27.285M Estimate — benzinga Aug 10, 2026 negative
- NEWS CeriBell Announces FDA 510(k) Clearance For Two New AI Algorithm Enhancements Integrated Directly Into Existing Cloud-Ba — benzinga Aug 10, 2026 positive
Generated 2026-08-14T11:47:19Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductCeribell System10-K Item 1A: 'We expect that revenue from sales of the Ceribell System will continue to account for almost all of our revenue for the foreseeable future.'
- HIGHGeographicUnited States sales100%10-K Item 1A: 'To date, all of our sales have been to customers in the United States.'
- HIGHSuppliertwo primary contract manufacturers in China10-K Item 1A: 'We rely on two primary contract manufacturers in China and maintain contractors in China who perform monitoring and quality inspection services.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Unprofitable operations — net margin -64.7%. Quality floor flags this regardless of sector context.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $22.91: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 6.0/10. Specifically: Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $21.31. Score 6.0/10, moderate confidence.
Take-profit target: $23.49 (+2.5% upside). Prior stop was $21.31. Stop-loss: $21.31.
Concentration risk — Product: Ceribell System; Concentration risk — Geographic: United States sales (100.0%); Target reached (2.5% upside).
CeriBell, Inc. trades at a P/E of N/A (forward -14.9). TrendMatrix value score: 4.8/10. Verdict: Sell.
14 analysts cover CBLL with a consensus score of 4.4/5. Average price target: $27.
What does CeriBell, Inc. do?CeriBell has developed the Ceribell System, an FDA-cleared point-of-care EEG platform paired with Clarity, an...
CeriBell has developed the Ceribell System, an FDA-cleared point-of-care EEG platform paired with Clarity, an AI-powered algorithm for detecting seizures and, since a December 2025 clearance, delirium in critically ill patients. The company generated 88% gross margins in fiscal 2025 from a recurring revenue model combining disposable Wearable sales and Clarity/portal subscription fees, has deployed to more than 600 U.S. hospitals, and to date has sold exclusively to customers in the United States. CeriBell relies on two primary contract manufacturers in China for assembly of its disposable Wea